CEO Dipal Doshi (Entrada)
March 31, 2021 07:30 AM EDTUpdated 08:26 AM
Financing

Piv­ot­ing to­ward neu­ro­mus­cu­lar dis­eases and Duchenne, En­tra­da locks down $116M crossover round

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

No­vo turns to Septer­na for oral obe­si­ty med­i­cines in deal worth up to $2.2B

SK, Car­lyle bol­ster blue­bird bio bid; Theri­ni Bio rais­es $39M

Lack of de­tail in Trump's drug price plan rais­es more ques­tions than an­swers

Ad­vo­ca­cy groups and ex­perts call for decade-long ban on germline edit­ing

A service from the Financial Times